Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Summary

EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 202...

Description

EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 202...

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Open original source

Related coverage